Texas A&M Researchers Test Far-UVC Technology to Reduce Airborne Pathogens in Poultry Houses

Texas, September 2026 — Researchers at Texas A&M University are advancing research into the use of far-UVC light as a potential non-pharmaceutical tool for reducing airborne pathogens in commercial poultry houses.

The research is particularly relevant to the poultry industry’s ongoing search for additional biosecurity technologies that could reduce pathogen transmission in high-density production environments, including pathogens associated with avian influenza.

The work is a developing research programme rather than a new commercial product launch, and the results should therefore not yet be interpreted as evidence that far-UVC can replace established poultry biosecurity measures.

What is far-UVC?

Far-UVC generally refers to ultraviolet light in the approximately 200–230 nm range, with 222 nm being a commonly studied wavelength.

The scientific rationale is straightforward: UV radiation can damage nucleic acids and interfere with microbial replication. Far-UVC is being investigated because its shorter wavelength has different penetration characteristics from conventional germicidal UV-C. The potential poultry application is particularly interesting because a poultry house presents an unusually difficult pathogen-control environment.

Large numbers of birds are housed together, ventilation continuously moves air, organic material can shield microorganisms, and pathogens can potentially circulate through airborne particles.

Texas A&M’s poultry application

Texas A&M researchers are testing whether far-UVC can reduce airborne microbial loads in poultry housing while maintaining bird safety.

The programme is moving into a later stage of its multiyear research effort, with testing designed to assess performance under increasingly realistic commercial poultry conditions. The research has included monitoring indicator microorganisms such as aerobic bacteria, coliforms and Staphylococcus aureus before and after exposure.

The underlying commercial question is whether far-UVC can achieve meaningful microbial reduction at poultry-house scale, rather than simply demonstrating antimicrobial activity under laboratory conditions.

Potential relevance to avian influenza

The technology has attracted attention because airborne and environmental pathogen control is an important component of poultry biosecurity. Highly pathogenic avian influenza (HPAI) remains one of the most consequential infectious-disease risks for global poultry production.

However, it is important to distinguish between: demonstrating reduction of indicator microorganisms

and demonstrating control of HPAI transmission in commercial poultry.

The Texas A&M work does not establish that far-UVC is an HPAI-control technology. That would require direct pathogen studies, appropriate biosafety protocols, field validation and evidence that reductions translate into lower infection rates.

Why the technology could matter commercially

If successful, far-UVC could eventually complement existing poultry-house systems such as:

• ventilation management;

• filtration;

• sanitation;

• controlled access;

• vaccination;

• environmental monitoring;

• litter management;

• personnel biosecurity.

The commercial proposition would be particularly attractive if far-UVC systems could operate continuously or semi-continuously without adversely affecting bird welfare, worker safety or production economics. That could potentially create a new technology category at the intersection of animal health, environmental control and agricultural engineering.

Key hurdles remain

There are several questions that need to be answered before commercial deployment can be assessed.

1. Bird safety: Long-duration exposure must be demonstrated under commercial conditions.

2. Worker safety: Poultry-house systems must operate within appropriate occupational exposure limits.

3. Real-world efficacy: Organic matter, dust and ventilation can reduce UV performance.

4. Pathogen-specific performance: Indicator-bacteria reductions do not automatically translate into equivalent reductions for viruses.

5. Economics: Capital cost, energy consumption, maintenance and replacement of UV components will determine commercial viability.

AHI Analyst view

Far-UVC should be viewed as a potential additional layer of poultry biosecurity, not as a replacement for vaccination, surveillance or farm-level biosecurity. The investment thesis is nevertheless interesting.

The poultry industry is increasingly looking for technologies that can reduce pathogen pressure without relying exclusively on antibiotics or conventional chemical disinfection. If far-UVC can demonstrate reliable pathogen reduction in commercial-scale environments while maintaining animal and worker safety, it could become an enabling technology for controlled-environment livestock production.

For animal-health investors and strategic companies, the important milestone is therefore not laboratory antimicrobial activity.

It is commercial-scale validation under real poultry-house conditions.